Are 5′-O-Carbamate-2′,3′-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs?

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 15, 2003, Pages 2459-2463

  Anastasi, Carole ^a,b   Vlieghe, Patrick ^b   Hantz, Olivier ^a   Schorr, Olivier ^a   Pannecouque, Christophe ^c   Witvrouw, Myriam ^c   De Clercq, Erik ^c   Clayette, Pascal ^d,e   Dereuddre Bosquet, Nathalie ^d,e   Dormont, Dominique ^d   Gondois Rey, Françoise ^a   Hirsch, Ivan ^a   Kraus, Jean Louis ^a  

^a INSERM   (France)

^b Laboratoire LAPHAL   (France)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^e SPI BIO   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; CYTIDINE DERIVATIVE; NUCLEOSIDE DERIVATIVE; PRODRUG; 5' O CARBAMATE 2',3' DIDEOXYTHIACYTIDINE; 5'-O-CARBAMATE-2',3'-DIDEOXYTHIACYTIDINE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL LYSATE; CONTROLLED STUDY; DRUG SCREENING; HEPATITIS B; HEPATITIS B VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; NONHUMAN; CELL LINE; CULTURE MEDIUM; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CELL LINE; CULTURE MEDIA; DEOXYCYTIDINE; HEPATITIS B VIRUS; HIV-1; HUMANS; PRODRUGS;

EID: 0037972012     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00496-7     Document Type: Article

References (14)

1. Aggarwal S.R., Gogu S.R., Rangan S.R., Agrawal K.C. J. Med. Chem. 33:1990;1505.
2. Vlieghe P., Bihel F., Clerc T., Pannecouque C., Witvrouw M., De Clercq E., Salles J.-P., Chermann J.-C., Kraus J.-L. J. Med. Chem. 44:2001;777.
3. Vlieghe P., Clerc T., Pannecouque C., Witvrouw M., De Clercq E., Salles J.-P., Chermann J.-C., Kraus J.-L. J. Med. Chem. 44:2001;3014.
4. Perez-Perez M.J., Balzarini J., De Clercq E., Camarasa M. J. Bioorg. Med. Chem. 1:1993;279.
5. Chang S.-L., Griesgraber G., Abraham T.W., Garg T., Song H., Zimmerman C.L., Wagner C.R. Nucleosides, Nucleotides and Nucleic Acids. 19:2000;87.
6. Fisher M.J., Giese U., Harms C.S., Kinnick M.D., Lindstrom T.D., McCowan J.R., Mest H.-J., Morin J.M. Jr., Mullaney J.T., Paal M., Rapp A., Rühter G., Ruterbories K.J., Sall D.J., Scarborough R.M., Schotten T., Stenzel W., Towner R.D., Um S.L., Utterback B.G., Wyss V.L., Jakubowski J.A. Bioorg. Med. Chem. Lett. 10:2000;385.
7. Martin S.F., Follows B.C., Hergenrother P.J., Franklin C.L. J. Org. Chem. 65:2000;4509.
8. Greenberg M.M., Matray T.J., Kahl J.D., Yoo D.J., Mc Minn D.L. J. Org. Chem. 63:1998;4062.
9. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewjin P., Desmyter J., De Clercq E. J. Virol. Methods. 20:1988;309.
10. 100 000 PBMCs were pre-treated for 30min with molecules and then infected with 75TCID50 of HIV-1-LAI strain. 7 days after infection supernatants were collected and HIV replication was measured by dosage of RT activity in cell culture supernatant.
11. Chu C., Ma T., Shanmuganathan K., Wang C., Xiang Y., Pai S., Yao G., Sommadossi J.P., Cheng Y. Antimicrob. Agents Chemother. 39:1995;979.
12. Kazmierski, W., Bevans, P., Furfine, E., Porter, D., Spaltenstein, A., Yang, H., 223rd National Meeting of the American Chemical Society, Orlando, FL, April 7-11, 2002.
13. Mc Intee E., Remmel R., Schinazi R., Abraham T., Wagner C. J. Med. Chem. 40:1997;3323.
14. Von Janta-Lipinsky M., Costisella B., Ochs H., Hübscher U., Hafkemeyer P., Matthes E. J. Med. Chem. 41:1998;2040.